Discovery Labs-DSCO's response to Surfaxin approvable letter deemed completeFly On The Wall "All News "
The FDA has accepted Discovery Labs' submission of November 1, 2007 as a complete response to the April 2006 Approvable Letter for Surfaxin(r), for the prevention of Respiratory Distress Syndrome in premature infants. The FDA has established May 1, 2008 as its target date to complete its review of the Surfaxin New Drug Application.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment